- Home
- CVKD vs SBFM Comparison
CVKD vs SBFM Comparison
Compare CVKD & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- SBFM
- Stock Information
- Founded
- CVKD 2022
- SBFM 2006
- Country
- CVKD United States
- SBFM United States
- Employees
- CVKD N/A
- SBFM N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- SBFM Health Care
- Exchange
- CVKD Nasdaq
- SBFM Nasdaq
- Market Cap
- CVKD 29.5M
- SBFM 7.7M
- IPO Year
- CVKD 2023
- SBFM N/A
- Fundamental
- Price
- CVKD $11.47
- SBFM $1.44
- Analyst Decision
- CVKD Strong Buy
- SBFM Strong Buy
- Analyst Count
- CVKD 1
- SBFM 1
- Target Price
- CVKD $32.00
- SBFM $15.00
- AVG Volume (30 Days)
- CVKD 33.0K
- SBFM 77.5K
- Earning Date
- CVKD 08-06-2025
- SBFM 08-15-2025
- Dividend Yield
- CVKD N/A
- SBFM N/A
- EPS Growth
- CVKD N/A
- SBFM N/A
- EPS
- CVKD N/A
- SBFM N/A
- Revenue
- CVKD N/A
- SBFM $36,234,578.00
- Revenue This Year
- CVKD N/A
- SBFM $192.48
- Revenue Next Year
- CVKD N/A
- SBFM N/A
- P/E Ratio
- CVKD N/A
- SBFM N/A
- Revenue Growth
- CVKD N/A
- SBFM 35.51
- 52 Week Low
- CVKD $5.70
- SBFM $1.17
- 52 Week High
- CVKD $22.90
- SBFM $8.78
- Technical
- Relative Strength Index (RSI)
- CVKD 40.38
- SBFM 45.66
- Support Level
- CVKD $10.02
- SBFM $1.39
- Resistance Level
- CVKD $13.71
- SBFM $1.54
- Average True Range (ATR)
- CVKD 1.08
- SBFM 0.11
- MACD
- CVKD -0.13
- SBFM -0.01
- Stochastic Oscillator
- CVKD 29.72
- SBFM 9.46
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.